STAFFORD, Texas — December 15, 2025 — Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, announced a preliminary analysis from its ongoing Phase III FLAMINGO-01 clinical trial, showing an approximately 80% reduction in breast cancer recurrence rates in the open-label, non-HLA-A*02 arm of the study. The data relate to GLSI-100, an investigational immunotherapy designed to prevent breast cancer recurrence, and mark a significant milestone as the first patients complete both the primary immunization series and booster vaccinations. The findings build on earlier Phase IIb results and highlight encouraging trends in efficacy, immune response, and safety.
Science Significance
Scientifically, the findings reinforce the therapeutic concept behind GLSI-100, a peptide-based immunotherapy targeting HER2/neu–expressing breast cancer. The preliminary analysis used two independent methodologies to estimate recurrence reduction in the absence of a direct placebo comparator, both converging on an ~80% reduction in recurrence rate after completion of the primary immunization series (PIS). Importantly, the data suggest that peak immune protection is achieved following the initial six vaccinations, with sustained benefit supported by booster doses. The consistency of immune response and safety trends across HLA subtypes further strengthens the biological rationale for broad applicability of this preventive immunotherapy strategy.
Regulatory Significance
From a regulatory perspective, FLAMINGO-01 is being conducted under a GCP-compliant, global Phase III framework, with both double-blinded placebo-controlled arms and an open-label arm designed to address immunogenetic diversity. The preliminary analysis was performed in a manner that maintains study blinding, underscoring adherence to regulatory expectations for data integrity. While the results are exploratory and not predictive of final outcomes, they support continued enrollment and treatment of non-HLA-A*02 patients and may inform future regulatory interactions, including interim analyses for superiority or futility as defined in the protocol.
Business Significance
Advertisement
Strategically, the update strengthens Greenwich LifeSciences’ clinical and corporate positioning by demonstrating scalability of efficacy signals beyond earlier Phase IIb populations. The non-HLA-A*02 arm includes 250 treated patients, representing a substantially larger dataset than prior studies and supporting the company’s ambition to address a broad, global patient population. Positive trends in recurrence reduction enhance the long-term value proposition of GLSI-100 and reinforce investor confidence in the FLAMINGO-01 program as the company advances toward key clinical and regulatory inflection points.
Patients’ Significance
For patients with HER2-positive breast cancer, recurrence remains a critical concern even after surgery and standard systemic therapy. The preliminary FLAMINGO-01 findings suggest that GLSI-100 may offer durable protection against recurrence, addressing a major unmet need in survivorship care. By focusing on prevention rather than treatment of metastatic disease, the approach has the potential to improve long-term outcomes, quality of life, and survival, while complementing existing standards of care. The favorable safety and immune response trends reported to date further support the therapy’s potential suitability for long-term preventive use.
Policy Significance
At the policy level, the results align with broader healthcare priorities emphasizing cancer prevention, immunotherapy innovation, and value-based outcomes. Preventive immunotherapies that significantly reduce recurrence could lower the long-term burden on healthcare systems by decreasing the need for costly metastatic treatments. The study also highlights the importance of inclusive trial designs that address genetic diversity, supporting policy efforts to ensure equitable access to next-generation cancer therapies across patient populations.
Greenwich LifeSciences’ preliminary FLAMINGO-01 analysis underscores the potential of GLSI-100 to redefine the prevention landscape for breast cancer recurrence. While the data remain early and will continue to mature, the observed ~80% reduction in recurrence rate, together with consistent immune and safety signals, provides a compelling scientific and regulatory foundation for continued development. For the cGxP.wire audience, the announcement exemplifies how rigorous clinical execution, immunological insight, and regulatory discipline converge to advance preventive oncology therapies toward meaningful patient impact.
Source: Greenwich LifeSciences Inc. press release
